01.12.2017 | Research article | Ausgabe 1/2017 Open Access

The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Electronic supplementary material
Background
Methods
Patient selection and the collection of clinicopathological parameters
HCC (624)
|
cHC-CCA (31)
|
IHCCA (239)
|
EHBCA (19)
|
p-value
|
|||
---|---|---|---|---|---|---|---|
Stem cell (16)
|
Classical (15)
|
CLC(24)
|
Non-CLC(215)
|
||||
Sex (M:F ratio)
|
4.9
|
2.2
|
14
|
2
|
2.9
|
1.1
|
0.001*
|
Male
|
518(83)
|
11(69)
|
14(93)
|
16(67)
|
160(74)
|
10(53)
|
0.001*
|
Female
|
106(17)
|
5(31)
|
1(7)
|
8(33)
|
55(26)
|
9(47)
|
|
Age (year, mean ± SD)
|
54 ± 10
|
51 ± 12
|
58 ± 8
|
60 ± 10
|
62 ± 9
|
58 ± 12
|
<0.001*
|
Chronic liver disease
|
593(95)
|
16(100)
|
12(80)
|
12(50)
|
39(18)
|
0(0)
|
<0.001*
|
Viral
|
557(94)
|
10(63)
|
9(75)
|
7(58)
|
27(69)
|
0(0)
|
<0.001*
|
Non-viral
|
36(6)
|
5(31)
|
3(25)
|
5(42)
|
12(31)
|
0(0)
|
|
pT stage (AJCC 7th)
|
|||||||
pT1
|
256(41)
|
9(56)
|
3(20)
|
7(29)
|
81(38)
|
1(5)
|
0.01*
|
pT2-pT4
|
360(58)
|
7(44)
|
12(80)
|
17(71)
|
131(61)
|
17(89)
|
|
Progress
|
|||||||
Recur or metastasis
|
395(63)
|
7(44)
|
10(67)
|
11(46)
|
144(67)
|
12(63)
|
<0.001*
|
PFS (median, month)
|
26
|
103
|
12
|
NA
|
11
|
20
|
<0.001*
|
Death
|
|||||||
Deceased
|
352(56)
|
6(38)
|
10(67)
|
6(25)
|
110(51)
|
18(95)
|
<0.001*
|
OS (median, month)
|
77
|
91
|
21
|
NA
|
61
|
18
|
<0.001*
|
Construction of tissue microarrays and immunohistochemical staining
Statistical analysis
Results
Differences in clinicopathological features according to histological type
Expression of YAP1 in 8 disease groups
Number
|
Negative
|
Positive
|
P-value
|
|
---|---|---|---|---|
CK19(−) HCC
|
491
|
482 (98)
|
9 (2)
|
<0.001*
|
CK19(−) scirrhous HCC
|
32
|
31 (97)
|
1 (3)
|
|
CK19(+) HCC
|
101
|
91 (90)
|
10 (10)
|
|
Stemness-feature Carcinoma
|
40
|
38 (95)
|
2 (5)
|
|
Combined HC-CCA, stem cell feature
|
16
|
15 (94)
|
1 (6)
|
|
Cholangiolocellular IHCCA
|
24
|
23 (96)
|
1 (4)
|
|
Combined HC-CCA, classical type
|
15
|
15 (100)
|
0 (0)
|
|
IHCCA, non-cholangiolocellular
|
215
|
192 (89)
|
23 (11)
|
|
EHBCA
|
19
|
15 (79)
|
4 (21)
|
Clinicopathological characteristics of HCCs and IHCCAs with positive YAP1 expression
N (%)
|
p-value
|
||
---|---|---|---|
Sex
|
Male[518] vs.
Female[106]
|
16(3) vs. 4 (4)
|
0.715
|
Age (yr)
|
≤55[324] vs.
>55[300]
|
9(3) vs. 11 (4)
|
0.681
|
Size (cm)
|
≤5.0[379] vs.
>5.0[235]
|
12(3) vs. 8 (3)
|
0.872
|
Multiplicity
|
Single[449] vs.
Multiple[169]
|
11(2) vs. 9 (5)
|
0.072
|
Vascular invasion
|
Absent[330] vs.
Present[286]
|
10(3) vs. 10 (3)
|
0.745
|
Large vessel invasion
|
Absent[578] vs.
Present[37]
|
18(3) vs. 2 (5)
|
0.446
|
pT stage (AJCC 7th)
|
pT1–2[486] vs.
pT3–4[138]
|
16(3) vs. 4 (3)
|
0.982
|
ES nuclear grade
|
1–2[300] vs.
3–4[313]
|
4(1) vs. 15 (5)
|
0.014*
|
Preoperative treatment
|
Done[261] vs.
Not done[315]
|
13(5) vs. 6 (2)
|
0.114
|
Serum AFP (ng/ml)
|
≤32[309] vs.
>32[289]
|
4(1) vs. 14 (5)
|
0.011*
|
Cell type
|
Hepatic[539] vs.
Non-hepatic[61]
|
17(3) vs. 2 (3)
|
0.958
|
Histologic pattern
|
Trabecular/acinar[487] vs.
Compact[113]
|
12(2) vs. 7 (6)
|
0.041*
|
Desmoplastic stroma
|
Absent[462] vs.
Present[113]
|
9(2) vs. 9 (8)
|
<0.001*
|
Expression of CK19
|
Negative[523] vs.
Positive[101]
|
10(2) vs. 10 (10)
|
<0.001*
|
Etiology of CLD
|
Viral[557] vs.
Non-viral[36]
|
19(3) vs. 0 (0)
|
0.621
|